Yesterday's announcement is still currently under rated IMO (announcement shown as per below image). I don't think the market fully understands what it means to have the USA govt reimburse the cost of use for FebriDx.
The current Total Available Market (TAM) for the FebriDx product in the US is currently estimated to be US $118 million dollars per annum (as per below slide presentation screenshot). That TAM is reported to increase to 1.7 billion after the CLIA waiver is achieved (as per blow presentation slide).
The US govt has just endorsed the use of FebriDx to the extent that the US govt will reimburse clinicians for the cost of use for Febridx (as per below image of announcement).
As the below article screenshot indicates:
"If there is positive incentive for adoption such as the clinician or facility getting paid, then they will use the product".Basically, the US govt will pay clinicians to use FebriDx, and the current market size for the FebriDx product is about US $118 million dollars per annum, with plans to expand that market size to 1.7 billion per annum in the near future.
IMO, it is pretty clear that LDX revenue is expected to significantly increase as a result of this announcement.
IMO, LDX is currently significantly undervalued (as per above attached link to previous post). 
(20min delay)